JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Alectinib (formerly AF802, CH5424802, RO5424802; trade name Alecensa) is a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor with potential antitumor activity. It inhibits ALK with IC50 value of 1.9 nM in cell-free assays. In 2017, Alectinib was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC).
References: Cancer Cell. 2011 May 17; 19(5):679-90; Bioorg Med Chem. 2012 Feb 1; 20(3):1271-80.
Related CAS: 1256589-74-8 (HCl); 1256580-46-7 (free base)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!